Daewoong Co Ltd

Daewoong Co Ltd maintains a capital structure with a debt-to-equity ratio of 0.75, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.34, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -67,386,736,149.9999 KRW, which may signal potential pressure on liquidity in the near term. In terms of profitability, Daewoong's return on equity (ROE) is 14.88%, which is relatively strong and suggests the company is generating solid returns for its shareholders. The return on assets (ROA) is 5.42%, indicating that the company is effectively utilizing its assets to generate profit. These metrics are in line with the industry's preferred metrics for pharmaceutical companies, which emphasize ROE and ROA as key indicators of financial health and operational efficiency. Daewoong's revenue is primarily concentrated in its domestic market, with a significant portion derived from the sale of generic and branded pharmaceutical products. The company's geographic exposure is limited, with the majority of its operations and revenue generated in South Korea. This concentration may expose the company to regional economic and regulatory risks, but it also allows for a focused and efficient operational strategy. The company's growth trajectory is expected to remain stable, with analysts forecasting a mean price target of 28,000.00 KRW, which is higher than the current market price of 20,200.00 KRW. The company's capital expenditure of -347,952,497,150.00 KRW indicates a significant investment in infrastructure and production capabilities, which could support future revenue growth. However, the company's net cash position is negative after subtracting total debt, which may limit its ability to pursue aggressive expansion or acquisition strategies. Daewoong faces several risk factors, including liquidity concerns due to its negative free cash flow and the potential for dilution, although the risk of dilution is currently assessed as low. The company's liquidity risk is moderate, and its credit risk is not explicitly detailed in the available data. The company's risk assessment highlights the importance of monitoring its cash flow and debt management strategies to ensure long-term financial stability. Recent events and filings indicate that Daewoong continues to focus on its core pharmaceutical business, with no significant changes in its strategic direction or major new product launches reported in the latest available data. The company's recent financial performance and operational activities suggest a stable and consistent approach to business operations.